Terms: = Sarcomas AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Prognosis
36 results:
1. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced nras-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract] [Full Text] [Related]
2. Colorectal Carcinoma With Sarcomatoid Components: Report of 15 Cases and Literature Review of an Exceedingly Rare Carcinoma Subtype.
Golconda U; McHugh KE; Allende DS; Collins K; Henn P; Lacambra M; Bejarano PA; Groisman GM; Loughrey MB; Monappa V; Zhang X; Hornick JL; Gonzalez RS
Am J Surg Pathol; 2024 Apr; 48(4):465-474. PubMed ID: 38155543
[TBL] [Abstract] [Full Text] [Related]
3. The diagnosis and treatment for primary cardiac angiosarcoma with n-ras gene mutation and MSI-L: A case report and review of the literature.
Sun J; Wei T; Sun B; Su J; Liu H; Wang D; Li X
Medicine (Baltimore); 2023 Dec; 102(51):e36682. PubMed ID: 38134104
[TBL] [Abstract] [Full Text] [Related]
4. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
[TBL] [Abstract] [Full Text] [Related]
6. [Clinicopathological features and prognosis of anorectal melanoma: A report of 68 cases].
Lai YM; Li ZW; Li H; Wu Y; Shi YF; Zhou LX; Lou YT; Cui CL
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):262-269. PubMed ID: 37042136
[TBL] [Abstract] [Full Text] [Related]
7. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
8. Prevalence and detection of actionable BRAF V600 and nras Q61 mutations in malignant peripheral nerve sheath tumor by droplet digital PCR.
Kao EY; Wakeman KM; Wu Y; Gross JM; Chen EY; Ricciotti RW; Liu YJ; Mantilla JG
Hum Pathol; 2022 Nov; 129():90-97. PubMed ID: 36067829
[TBL] [Abstract] [Full Text] [Related]
9. Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.
Zhao H; Dong Z; Wan D; Cao W; Xing H; Liu Z; Fan J; Wang H; Lu R; Zhang Y; Cheng Q; Jiang Z; He F; Xie X; Guo R
Sci Rep; 2022 Apr; 12(1):6752. PubMed ID: 35474239
[TBL] [Abstract] [Full Text] [Related]
10. Morbidity and long-term results in patients with wild and mutant type Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations undergoing colorectal cancer surgery.
Aziret M; Subasi O; Bilir C; Tozlu M; Altıntoprak F; Karaman K; Ercan M; Celebi F
Ann Ital Chir; 2022; 92():65-77. PubMed ID: 35342104
[TBL] [Abstract] [Full Text] [Related]
11. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Giuffrè G; Donini A; Fugazzola P; Faviana P; Sorrentino L; Scapinello A; Del Bianco P; Sommariva A
Ann Surg Oncol; 2022 Jun; 29(6):3405-3417. PubMed ID: 34783946
[TBL] [Abstract] [Full Text] [Related]
12. Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.
Paulsson JO; Rafati N; DiLorenzo S; Chen Y; Haglund F; Zedenius J; Juhlin CC
J Clin Endocrinol Metab; 2021 Oct; 106(11):3265-3282. PubMed ID: 34171097
[TBL] [Abstract] [Full Text] [Related]
13. Primary Mucinous Cystadenocarcinoma of the Breast: A Rare Case Report With Review of Literature.
Jain E; Kumar A; Jain R; Sharma S
Int J Surg Pathol; 2021 Oct; 29(7):740-746. PubMed ID: 33635116
[TBL] [Abstract] [Full Text] [Related]
14. Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder.
Tripathi K; Goel A; Singhai A; Garg M
Mol Biol Rep; 2021 Mar; 48(3):2183-2199. PubMed ID: 33620658
[TBL] [Abstract] [Full Text] [Related]
15. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
[TBL] [Abstract] [Full Text] [Related]
16. Genetic Characterization of Pediatric sarcomas by Targeted RNA Sequencing.
Avenarius MR; Miller CR; Arnold MA; Koo S; Roberts R; Hobby M; Grossman T; Moyer Y; Wilson RK; Mardis ER; Gastier-Foster JM; Pfau RB
J Mol Diagn; 2020 Oct; 22(10):1238-1245. PubMed ID: 32745614
[TBL] [Abstract] [Full Text] [Related]
17. Post-radiotherapy vascular lesions of the breast: immunohistochemical and molecular features of 74 cases with long-term follow-up and literature review.
Corradini AG; Asioli S; Morandi L; Brotto M; Righi A; Iommi M; Agostinelli C; Rucci P; Asioli S; Sapino A; Viale G; Foschini MP
Histopathology; 2020 Aug; 77(2):293-302. PubMed ID: 32043616
[TBL] [Abstract] [Full Text] [Related]
18. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic role of nras isoforms in Chinese melanoma patients.
Yan J; Xu L; Yu J; Wu X; Dai J; Xu T; Yu H; Guo J; Kong Y
Melanoma Res; 2019 Jun; 29(3):263-269. PubMed ID: 30489482
[TBL] [Abstract] [Full Text] [Related]
20. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.
Agaram NP; LaQuaglia MP; Alaggio R; Zhang L; Fujisawa Y; Ladanyi M; Wexler LH; Antonescu CR
Mod Pathol; 2019 Jan; 32(1):27-36. PubMed ID: 30181563
[TBL] [Abstract] [Full Text] [Related]
[Next]
